{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:55:38Z","timestamp":1761710138915,"version":"3.38.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":372,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30CA086862"],"award-info":[{"award-number":["P30CA086862"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ctarc.2025.100864","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T17:09:38Z","timestamp":1736442578000},"page":"100864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeting transforming growth factor-\u03b21 by methylseleninic acid\/seleno-L-methionine in clear cell renal cell carcinoma: Mechanisms and therapeutic potential"],"prefix":"10.1016","volume":"42","author":[{"given":"Aseel O.","family":"Rataan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M.","family":"Geary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman S.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youcef M.","family":"Rustum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1923-6633","authenticated-orcid":false,"given":"Aliasger K.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2025.100864_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100864_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10112953","article-title":"Diagnostic and prognostic biomarkers in renal clear cell carcinoma","volume":"10","author":"Weaver","year":"2022","journal-title":"Biomedicines."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100864_bib0003","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/onc.2016.272","article-title":"Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma","volume":"36","author":"Thompson","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2025.100864_bib0004","doi-asserted-by":"crossref","unstructured":"Chhabra, R. and M. Nanjundan, Lysophosphatidic acid reverses temsirolimus-induced changes in lipid droplets and mitochondrial networks in renal cancer cells. Public Library of Science One, 2020. 15(6): p. e0233887.","DOI":"10.1371\/journal.pone.0233887"},{"issue":"S10","key":"10.1016\/j.ctarc.2025.100864_bib0005","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/cncr.24238","article-title":"Complexity of tumor vasculature in clear cell renal cell carcinoma","volume":"115","author":"Qian","year":"2009","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ctarc.2025.100864_bib0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.14715\/cmb\/2018.64.7.9","article-title":"Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma","volume":"64","author":"Campagna","year":"2018","journal-title":"Cellular and Mol. Biol. (Noisy-le-Grand)"},{"issue":"7","key":"10.1016\/j.ctarc.2025.100864_bib0007","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","article-title":"Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies","volume":"17","author":"Makhov","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ctarc.2025.100864_bib0008","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejca.2020.06.008","article-title":"Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: a meta-analysis of randomised clinical trials with immune checkpoint inhibitors","volume":"136","author":"Iacovelli","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2025.100864_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from 42-month follow-up of KEYNOTE-426","volume":"39","author":"Rini","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100864_bib0010","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100864_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010099","article-title":"Sarcomatoid dedifferentiation in renal cell carcinoma: from novel molecular insights to new clinical opportunities","volume":"12","author":"Debien","year":"2019","journal-title":"Cancers. (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100864_bib0012","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13046-021-01961-3","article-title":"Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma","volume":"40","author":"Sharma","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100864_bib0013","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1357-2725(97)00128-3","article-title":"Molecules in focus transforming growth factor-beta (TGF-\u03b2)","volume":"30","author":"Clark","year":"1998","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100864_bib0014","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1080\/21645515.2017.1327107","article-title":"Transforming growth factor-\u03b2: a therapeutic target for cancer","volume":"13","author":"Haque","year":"2017","journal-title":"Hum. Vaccin. Immunother"},{"issue":"5","key":"10.1016\/j.ctarc.2025.100864_bib0015","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.humpath.2011.06.019","article-title":"Sarcomatoid conversion of clear cell renal cell carcinoma in relation to epithelial-to-mesenchymal transition","volume":"43","author":"Bostr\u00f6m","year":"2012","journal-title":"Hum. Pathol."},{"issue":"2747","key":"10.1016\/j.ctarc.2025.100864_bib0016","article-title":"Liq_ccRCC: identification of clear cell renal cell carcinoma based on the integration of clinical liquid indices","volume":"10","author":"Zhao","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100864_bib0017","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/ijms20010225","article-title":"Methylseleninic acid induces lipid peroxidation and radiation sensitivity in head and neck cancer cells","volume":"20","author":"Lafin","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100864_bib0018","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1158\/1078-0432.CCR-08-0212","article-title":"Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs","volume":"14","author":"Bhattacharya","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.100864_bib0019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2018.05.001","article-title":"Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatment","volume":"127","author":"Gandin","year":"2018","journal-title":"Free Radic. Biol. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100864_bib0020","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3390\/ijms23042215","article-title":"Potential role of selenium in the treatment of cancer and viral infections","volume":"23","author":"Rataan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2025.100864_bib0021","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/1471-2407-12-293","article-title":"Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition","volume":"12","author":"Chintala","year":"2012","journal-title":"BMC. Cancer"},{"issue":"10","key":"10.1016\/j.ctarc.2025.100864_bib0022","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.3390\/ijms23105604","article-title":"MicroRNA expression in clear cell renal cell carcinoma cell lines and tumor biopsies: potential therapeutic targets","volume":"23","author":"Swearson","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100864_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113378","article-title":"Non-coding micro RNAs and hypoxia-inducible factors are selenium targets for development of a mechanism-based combination strategy in clear-cell renal cell carcinoma-bench-to-bedside therapy","volume":"19","author":"Rustum","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"41","key":"10.1016\/j.ctarc.2025.100864_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202206121","article-title":"Tumor selective metabolic reprogramming as a prospective PD-L1 depression strategy to reactivate immunotherapy","volume":"34","author":"Liu","year":"2022","journal-title":"Adv. Mater."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100864_bib0025","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1021\/acsnano.3c10117","article-title":"Mitochondrial disruption nanosystem simultaneously depressed programmed death Ligand-1 and transforming growth factor-\u03b2 to overcome photodynamic immunotherapy resistance","volume":"18","author":"Jiang","year":"2024","journal-title":"ACS. Nano"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100864_bib0026","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.intimp.2009.09.020","article-title":"Sodium selenite inhibits the expression of VEGF, TGF\u03b21 and IL-6 induced by LPS in human PC3 cells via TLR4-NF-KB signaling blockage","volume":"10","author":"Pei","year":"2010","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.ctarc.2025.100864_bib0027","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","volume":"9","author":"Jafari","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ctarc.2025.100864_bib0028","doi-asserted-by":"crossref","first-page":"28597","DOI":"10.1038\/srep28597","article-title":"Metformin is a novel suppressor for transforming growth factor (TGF)-\u03b21","volume":"6","author":"Xiao","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100864_bib0029","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clim.2005.01.005","article-title":"PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis","volume":"115","author":"Ding","year":"2005","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100864_bib0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/jcla.10074","article-title":"Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement","volume":"17","author":"Yang","year":"2003","journal-title":"J. Clin. Lab. Anal."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100864_bib0031","first-page":"317","article-title":"Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue","volume":"32","author":"Mitropoulos","year":"2004","journal-title":"Urolithiasis Res."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100864_bib0032","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1186\/s12885-024-12400-9","article-title":"Factors correlating the expression of PD-L1","volume":"24","author":"Lu","year":"2024","journal-title":"BMC. Cancer"},{"issue":"11","key":"10.1016\/j.ctarc.2025.100864_bib0033","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","article-title":"PD-L1 expression in nonclear-cell renal cell carcinoma","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100864_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.06.014","article-title":"Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma","volume":"33","author":"Minardi","year":"2015","journal-title":"Urol. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100864_bib0035","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1349-7006.2009.01100.x","article-title":"Active TGF-beta1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence","volume":"100","author":"Hawinkels","year":"2009","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100864_bib0036","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/nep.13430","article-title":"Metformin inhibits TGF-beta 1-induced MCP-1 expression through BAMBI-mediated suppression of MEK\/ERK1\/2 signalling","volume":"24","author":"Liang","year":"2019","journal-title":"Nephrology. (Carlton)"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100864_bib0037","doi-asserted-by":"crossref","first-page":"28597","DOI":"10.1038\/srep28597","article-title":"Metformin is a novel suppressor for transforming growth factor (TGF)-\u03b21","volume":"6","author":"Xiao","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2025.100864_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020408","article-title":"Outcomes associated with first-line anti-PD-1\/PD-L1 agents vs. sunitinib in patients with sarcomatoid renal cell carcinoma: a systematic review and meta-analysis","volume":"12","author":"Buonerba","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ctarc.2025.100864_bib0039","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2019.10.025","article-title":"Efficacy of nivolumab plus ipilimumab according to number of IMDC risk factors in CheckMate 214","volume":"77","author":"Escudier","year":"2020","journal-title":"Eur. Urol."},{"issue":"21","key":"10.1016\/j.ctarc.2025.100864_bib0040","first-page":"13","article-title":"First-line treatment of metastatic clear cell renal cell carcinoma: what are the most appropriate combination therapies?","author":"Vano","year":"2021","journal-title":"Cancers. (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100864_bib0041","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbcan.2013.10.001","article-title":"Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms","volume":"1845","author":"Buczek","year":"2014","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"10.1016\/j.ctarc.2025.100864_bib0042","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3389\/fgene.2019.00320","article-title":"Molecular mechanisms in clear cell renal cell carcinoma: role of miRNAs and hypermethylated miRNA genes in crucial oncogenic pathways and processes","volume":"10","author":"Braga","year":"2019","journal-title":"Front. Genet."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100864_bib0043","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00428-021-03256-6","article-title":"TGFB1 mRNA expression is associated with poor prognosis and specific features of inflammation in ccRCC","volume":"480","author":"Takahara","year":"2022","journal-title":"Eur. J. Pathol. Virchows Archiv"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100864_bib0044","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13045-022-01349-6","article-title":"TGF-\u03b2 signaling in the tumor metabolic microenvironment and targeted therapies","volume":"15","author":"Shi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ctarc.2025.100864_bib0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1479-5876-10-183","article-title":"TGF-\u03b2 - an excellent servant but a bad master","volume":"10","author":"Kubiczkova","year":"2012","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100864_bib0046","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bbrc.2013.04.054","article-title":"Effects of TGF-\u03b2 signaling in clear cell renal cell carcinoma cells","volume":"435","author":"Bostr\u00f6m","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ctarc.2025.100864_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111046","article-title":"Recent progress in TGF-\u03b2 inhibitors for cancer therapy","volume":"134","author":"Huang","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100864_bib0048","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","article-title":"Induction of heart valve lesions by small-molecule ALK5 inhibitors","volume":"39","author":"Anderton","year":"2011","journal-title":"Toxicol. Pathol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100864_bib0049","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-017-3245-5","article-title":"A phase 1 study of anti-TGF\u03b2 receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors","volume":"79","author":"Tolcher","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100864_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/biom9110743","article-title":"A perspective on the development of TGF-\u03b2 inhibitors for cancer treatment","volume":"9","author":"Huynh","year":"2019","journal-title":"Biomolecules."},{"issue":"26","key":"10.1016\/j.ctarc.2025.100864_bib0051","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202401394","article-title":"Mitochondria energy metabolism depression as novel adjuvant to sensitize radiotherapy and inhibit radiation induced-pulmonary fibrosis","volume":"11","author":"Zhou","year":"2024","journal-title":"Adv. Sci."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100864_bib0052","doi-asserted-by":"crossref","first-page":"10765","DOI":"10.18632\/oncotarget.24297","article-title":"Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development","volume":"9","author":"Zakharia","year":"2018","journal-title":"Oncotarget."},{"issue":"7","key":"10.1016\/j.ctarc.2025.100864_bib0053","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1158\/1078-0432.CCR-03-0268","article-title":"Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts","volume":"10","author":"Cao","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.100864_bib0054","first-page":"38","article-title":"The TGF\u03b2-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100864_bib0055","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41467-019-09634-8","article-title":"Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance","volume":"10","author":"Li","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100864_bib0056","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/pcmr.12578","article-title":"MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway","volume":"30","author":"Koetz-Ploch","year":"2017","journal-title":"Pigment Cell Melanoma Res."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100864_bib0057","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"issue":"34","key":"10.1016\/j.ctarc.2025.100864_bib0058","doi-asserted-by":"crossref","first-page":"24171","DOI":"10.1074\/jbc.M604507200","article-title":"Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression","volume":"281","author":"McMahon","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100864_bib0059","doi-asserted-by":"crossref","first-page":"e59918","DOI":"10.1371\/journal.pone.0059918","article-title":"TGF-Beta suppresses VEGFA-mediated angiogenesis in colon cancer metastasis","volume":"8","author":"Geng","year":"2013","journal-title":"PLoS. One"},{"issue":"10","key":"10.1016\/j.ctarc.2025.100864_bib0060","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm3434","article-title":"TGF\u03b2 signalling in context","volume":"13","author":"Massagu\u00e9","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100864_bib0061","first-page":"234","article-title":"Regulation and Signaling of TGF-\u03b2 Autoinduction","volume":"10","author":"Hariyanto","year":"2021","journal-title":"Int. J. Mol. Cell. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100864_bib0062","doi-asserted-by":"crossref","first-page":"e23387","DOI":"10.1002\/jbt.23387","article-title":"Methylseleninic acid induces apoptosis of human bladder cancer cells through the ROS-mediated mitochondrial pathway","volume":"37","author":"Chen","year":"2023","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100864_bib0063","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126614","article-title":"The main cytotoxic effects of methylseleninic acid on various cancer cells","volume":"22","author":"Varlamova","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T23:14:20Z","timestamp":1740870860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":63,"alternative-id":["S2468294225000024"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100864","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting transforming growth factor-\u03b21 by methylseleninic acid\/seleno-L-methionine in clear cell renal cell carcinoma: Mechanisms and therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100864"}}